Vestis · Benefits Renewal

Vestis's renewal: the oncology line item

A newly independent company gets to choose its vendor stack from scratch. The oncology line — the fastest-growing on any self-funded plan — is one worth getting right the first time.

A 1% improvement on Vestis's plan is worth
~$3.5M / year
A clean-sheet vendor decision is the rare chance to capture it from day one.
Total annual plan spend
~$350M
~20,000 employees × $17,496 national avg cost.
Estimated oncology spend
~$84M
23.9% of plan spend — the line that grows fastest.
Single-claim exposure
$4.3M
Highest single cancer claim in 2024 — now fully on your own balance sheet.

The advantage of building the stack from scratch

Coming out of the Aramark spin-off, Vestis owns its benefits strategy outright — and a route-delivery and plant workforce that skews older carries real cancer exposure. Most employers inherit a patchwork of point solutions and never rationalize the oncology line. You don't have that legacy. You get to put the right navigator in place before the cost compounds.

ClearOnc is that navigator — Moffitt-powered. Right diagnosis path, right site of care, right specialty-drug route, with reporting that proves the return. The cleanest time to add it is the renewal you're designing now.

Where the 1% hides

The gaps that inflate the oncology line in plans like yours — each one is something ClearOnc closes from the start.

1 in 3
cancer patients ever get a survivorship care plan — driving avoidable recurrence cost.
8%
of lung-cancer patients get full NCCN biomarker testing — so plans fund therapies that can't work.
11 of 20
costliest injectable drugs treat cancer — specialty-drug routing is where dollars leak.
88%
of employers are actively evaluating new health vendors — you get to choose first, and well.

20 minutes, while the stack is still being built

We'll walk Vestis's modeled oncology exposure and where a navigator pays for itself.

Book your oncology spend review → Run your full breakdown